Novocure Ltd. | Mutual Funds
Mutual Funds that own Novocure Ltd.
Fidelity Growth Company Fund
2,824,236
3.04%
830,953
0.26%
07/31/2018
Vanguard Small Cap Index Fund
1,710,152
1.84%
22,512
0.08%
07/31/2018
Vanguard Total Stock Market Index Fund
1,707,169
1.84%
16,513
0.01%
07/31/2018
iShares Russell 2000 ETF
1,507,941
1.62%
-804
0.14%
09/06/2018
Fidelity Series Growth Company Fund
1,070,000
1.14%
234,414
0.36%
07/31/2018
iShares Nasdaq Biotechnology ETF
1,048,668
1.12%
-13,713
0.48%
09/06/2018
Vanguard Small Cap Growth Index Fund
976,734
1.05%
15,169
0.17%
07/31/2018
Ivy Small Cap Growth Fund
914,649
0.99%
0
1.56%
06/30/2018
Baillie Gifford Overseas Growth Fund - American Fund
796,467
0.86%
62,515
1.71%
04/30/2018
iShares Russell 2000 Growth ETF
694,318
0.75%
0
0.27%
09/06/2018
| Address |
No. 4 The Forum
St. Helier Jersey JE2 4UF
United Kingdom
|
|
Employees
|
- |
| Website |
http://www.novocure.com |
| Updated |
07/08/2019 |
| Novocure Ltd. operates as an oncology company. It enages in developing its propriety technoclogy, Tumor Treating Fields, which uses electric fields tuned to specific frequencies to disrupt cancer cell division, inhibiting tumor growth, and causing affected cancer cells to die. The company was founded by Yoram Palti in 2000 and is headquartered in St. |
